Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

NCT04892849 · clinicaltrials.gov ↗

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
NSCLC
Esophageal Cancer
Urothelial Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma of the Skin
Small Cell Bronchial Carcinomas

Interventions

OTHER: Conventional Therapy acc. to prevailing clincal approved schemes

Sponsor

University of Erlangen-Nürnberg Medical School